Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.

Tiemersma E, van den Hof S, Dravniece G, Wares F, Molla Y, Permata Y, Lukitosari E, Quelapio M, Aung ST, Aung KM, Thuy HT, Hoa VD, Sulaimanova M, Sagyndikova S, Makhmudova M, Soliev A, Kimerling M.

Eur Respir Rev. 2019 Oct 11;28(153). pii: 180115. doi: 10.1183/16000617.0115-2018. Print 2019 Sep 30. Review.

2.

Genotypes and genetic characters of Mycobacterium tuberculosis from Myanmar using three typing methods.

Ei PW, Lee JS, Aung WW, Yeun K, Korma W, Nyunt WW, Swe TL, Htwe MM, Win SM, Aung ST, Chang CL, Lee H.

Infect Genet Evol. 2019 Nov;75:104005. doi: 10.1016/j.meegid.2019.104005. Epub 2019 Aug 19.

PMID:
31437559
3.

Magnitude and reasons for pre-diagnosis attrition among presumptive multi-drug resistant tuberculosis patients in Bago Region, Myanmar: A mixed methods study.

Oo T, Kyaw KWY, Soe KT, Saw S, Satyanarayana S, Aung ST.

Sci Rep. 2019 May 10;9(1):7189. doi: 10.1038/s41598-019-43562-3.

4.

Pre-treatment loss to follow-up and treatment delay among bacteriologically-confirmed tuberculosis patients diagnosed in Mandalay Region, Myanmar.

Htwe KK, Kyaw NTT, Kumar AMV, Kyaw KWY, Oo MM, Thwin T, Saw S, Aung ST.

Trop Med Health. 2019 May 2;47:30. doi: 10.1186/s41182-019-0154-9. eCollection 2019.

5.

Fully vs. partially integrated services for TB-HIV in Myanmar: a health services review and a cohort study.

Kyi MS, Aung ST, Oo HN, Chongsuvivatwong V.

Int J Tuberc Lung Dis. 2019 Apr 1;23(4):498-506. doi: 10.5588/ijtld.18.0397.

PMID:
31064630
6.

Corrigendum: Hyperglycemia and Risk of All-cause Mortality Among People Living With HIV With and Without Tuberculosis Disease in Myanmar (2011-2017).

Kyaw NTT, Satyanarayana S, Oo HN, Kumar AMV, Harries AD, Aung ST, Kyaw KWY, Phyo KH, Aung TK, Magee MJ.

Open Forum Infect Dis. 2019 Apr 2;6(4):ofz143. doi: 10.1093/ofid/ofz143. eCollection 2019 Apr.

7.

High prevalence and incidence of tuberculosis in people living with the HIV in Mandalay, Myanmar, 2011-2017.

Phyo KH, Oo MM, Harries AD, Saw S, Aung TK, Moe J, Thuya SS, Mon YY, Min AC, Naing NN, Kyi MS, Aung ST, Oo HN.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):349-357. doi: 10.5588/ijtld.18.0436.

PMID:
30871667
8.

IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.

Kyaw NTT, Kumar AMV, Kyaw KWY, Satyanarayana S, Magee MJ, Min AC, Moe J, Aung ZZ, Aung TK, Oo MM, Soe KT, Oo HN, Aung ST, Harries AD.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):322-330. doi: 10.5588/ijtld.18.0448.

PMID:
30871663
9.

Sputum smear-positive, Xpert® MTB/RIF-negative results: magnitude and treatment outcomes of patients in Myanmar.

Phyu MH, Kyaw KWY, Myint Z, Thida A, Satyanarayana S, Aung ST.

Public Health Action. 2018 Dec 21;8(4):181-186. doi: 10.5588/pha.18.0056.

10.

How many sputum samples should be examined during follow-up of tuberculosis patients in Myanmar: two or one?

Win EE, Kumar AMV, Kyaw NTT, Aye NN, Hteik KM, Saw S, Oo MM, Kyaw KWY, Aung ST, Tun TL.

Public Health Action. 2018 Dec 21;8(4):169-174. doi: 10.5588/pha.18.0041.

11.

Hyperglycemia and Risk of All-cause Mortality Among People Living With HIV With and Without Tuberculosis Disease in Myanmar (2011-2017).

Kyaw NTT, Satyanarayana S, Oo HN, Kumar AMV, Harries AD, Aung ST, Kyaw KWY, Phyo KH, Aung TK, Magee MJ.

Open Forum Infect Dis. 2018 Dec 28;6(1):ofy355. doi: 10.1093/ofid/ofy355. eCollection 2019 Jan. Erratum in: Open Forum Infect Dis. 2019 Apr 02;6(4):ofz143.

12.

Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study.

Htun YM, Khaing TMM, Aung NM, Yin Y, Myint Z, Aung ST, Soonthornworasiri N, Silachamroon U, Kasetjaroen Y, Kaewkungwal J.

PLoS One. 2018 Dec 31;13(12):e0209932. doi: 10.1371/journal.pone.0209932. eCollection 2018.

13.

Evolution of Tuberculosis/Human Immunodeficiency Virus Services among Different Integrated Models in Myanmar: A Health Services Review.

Kyi MS, Aung ST, McNeil E, Chongsuvivatwong V.

Trop Med Infect Dis. 2018 Dec 24;4(1). pii: E2. doi: 10.3390/tropicalmed4010002.

14.

Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study.

Htun YM, Khaing TMM, Yin Y, Myint Z, Aung ST, Hlaing TM, Soonthornworasiri N, Silachamroon U, Kasetjaroen Y, Kaewkungwal J.

BMC Health Serv Res. 2018 Nov 20;18(1):878. doi: 10.1186/s12913-018-3715-4.

15.

Microbiome dataset from the upper respiratory tract of patients living with HIV, HIV/TB and TB from Myanmar.

Htun KS, Fong Y, Kyaw AA, Aung ST, Oo KZ, Zaw T, Lockhart PJ, Russell B, Cook GM, Aung HL, Hlaing TM.

Data Brief. 2018 Oct 4;21:354-357. doi: 10.1016/j.dib.2018.10.003. eCollection 2018 Dec.

16.

Acquired Resistance to Antituberculosis Drugs.

Aung HL, Nyunt WW, Fong Y, Russell B, Cook GM, Aung ST.

Emerg Infect Dis. 2018 Nov;24(11):2134. doi: 10.3201/eid2411.180465. No abstract available.

17.

Treatment outcome of tuberculosis patients detected using accelerated vs. passive case finding in Myanmar.

Khaing PS, Kyaw NTT, Satyanarayana S, Oo NL, Aung TH, Oo HM, Kyaw KWY, Soe KT, Thein S, Thwin T, Aung ST.

Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1145-1151. doi: 10.5588/ijtld.18.0038.

PMID:
30236181
18.

Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar.

Wai PP, Shewade HD, Kyaw NTT, Thein S, Si Thu A, Kyaw KWY, Aye NN, Phyo AM, Maung HMW, Soe KT, Aung ST.

PLoS One. 2018 Mar 29;13(3):e0194087. doi: 10.1371/journal.pone.0194087. eCollection 2018.

19.

Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?

Htet KKK, Soe KT, Kumar AMV, Saw S, Win Maung HM, Myint Z, Khine TMM, Aung ST.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):385-392. doi: 10.5588/ijtld.17.0452.

PMID:
29562985
20.

Evaluation of a tuberculosis active case finding project in peri-urban areas, Myanmar: 2014-2016.

Aye S, Majumdar SS, Oo MM, Tripathy JP, Satyanarayana S, Kyaw NTT, Kyaw KWY, Oo NL, Thein S, Thu MK, Soe KT, Aung ST.

Int J Infect Dis. 2018 May;70:93-100. doi: 10.1016/j.ijid.2018.02.012. Epub 2018 Feb 21.

21.

National scale-up of tuberculosis-human immunodeficiency virus collaborative activities in Myanmar from 2005 to 2016 and tuberculosis treatment outcomes for patients with human immunodeficiency virus-positive tuberculosis in the Mandalay Region in 2015.

Theingi P, Harries AD, Wai KT, Shewade HD, Saw S, Win T, Thein S, Kyi MS, Nyunt Oo H, Aung ST.

Trans R Soc Trop Med Hyg. 2017 Sep 1;111(9):402-409. doi: 10.1093/trstmh/trx073.

22.

High treatment success rate among multidrug-resistant tuberculosis patients in Myanmar, 2012-2014: a retrospective cohort study.

Thu MK, Kumar AMV, Soe KT, Saw S, Thein S, Mynit Z, Maung HMW, Aung ST.

Trans R Soc Trop Med Hyg. 2017 Sep 1;111(9):410-417. doi: 10.1093/trstmh/trx074.

PMID:
29351672
23.

Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.

Ei PW, Aung WW, Nyunt WW, Swe TL, Htwe MM, Win SM, Aung ST, Chang CL, Lee HY, Lee JS.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):47-53. doi: 10.5588/ijtld.17.0321.

PMID:
29297425
24.

Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar.

Aung WW, Ei PW, Nyunt WW, Htwe MM, Win SM, Aye KT, Mon AS, Aung ST, Chang CL, Lee JS.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01984-17. doi: 10.1128/AAC.01984-17. Print 2018 Mar. No abstract available.

25.

Patients with MDR-TB on domiciliary care in programmatic settings in Myanmar: Effect of a support package on preventing early deaths.

Wai PP, Shewade HD, Kyaw NTT, Kyaw KWY, Thein S, Si Thu A, Oo MM, Htwe PS, Tun MMT, Win Maung HM, Soe KT, Aung ST.

PLoS One. 2017 Dec 20;12(12):e0187223. doi: 10.1371/journal.pone.0187223. eCollection 2017.

26.

Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar.

Aung HL, Tun T, Nyunt WW, Fong Y, Crump JA, Thinn KK, Aung ST, Cook GM.

Infect Dis (Lond). 2018 May;50(5):388-390. doi: 10.1080/23744235.2017.1404632. Epub 2017 Dec 1. No abstract available.

PMID:
29192532
27.

Engagement of public and private medical facilities in tuberculosis care in Myanmar: contributions and trends over an eight-year period.

Nwe TT, Saw S, Le Win L, Mon MM, van Griensven J, Zhou S, Chinnakali P, Shah S, Thein S, Aung ST.

Infect Dis Poverty. 2017 Sep 1;6(1):123. doi: 10.1186/s40249-017-0337-8.

28.

Evaluation of the genotype MTBDRsl test for detection of second-line drug resistance in drug-resistant Mycobacterium tuberculosis strains in Myanmar.

Nyunt WW, Aung ST, Cook GM, Aung HL.

Infect Dis (Lond). 2017 Nov - Dec;49(11-12):865-866. doi: 10.1080/23744235.2017.1341056. Epub 2017 Jun 20. No abstract available.

PMID:
28631943
29.

Active case-finding for tuberculosis by mobile teams in Myanmar: yield and treatment outcomes.

Myint O, Saw S, Isaakidis P, Khogali M, Reid A, Hoa NB, Kyaw TT, Zaw KK, Khaing TMM, Aung ST.

Infect Dis Poverty. 2017 Jun 2;6(1):77. doi: 10.1186/s40249-017-0291-5.

30.

Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.

Hlaing NKT, Mitrani RA, Aung ST, Phyo WW, Serper M, Kyaw AMM, Bwa AH, Win KM, Reddy KR.

J Viral Hepat. 2017 Nov;24(11):927-935. doi: 10.1111/jvh.12721. Epub 2017 Jun 10.

PMID:
28475232
31.

First 2 Extensively Drug-Resistant Tuberculosis Cases From Myanmar Treated With Bedaquiline.

Aung HL, Nyunt WW, Fong Y, Cook GM, Aung ST.

Clin Infect Dis. 2017 Aug 1;65(3):531-532. doi: 10.1093/cid/cix365. No abstract available.

PMID:
28444149
32.

The contribution of a non-governmental organisation's Community Based Tuberculosis Care Programme to case finding in Myanmar: trend over time.

Maung HM, Saw S, Isaakidis P, Khogali M, Reid A, Hoa NB, Zaw KK, Thein S, Aung ST.

Infect Dis Poverty. 2017 Apr 3;6(1):51. doi: 10.1186/s40249-017-0253-y.

33.

International non-governmental organizations' provision of community-based tuberculosis care for hard-to-reach populations in Myanmar, 2013-2014.

Soe KT, Saw S, van Griensven J, Zhou S, Win L, Chinnakali P, Shah S, Mon MM, Aung ST.

Infect Dis Poverty. 2017 Mar 24;6(1):69. doi: 10.1186/s40249-017-0285-3.

34.

Different challenges, different approaches and related expenditures of community-based tuberculosis activities by international non-governmental organizations in Myanmar.

Han WW, Saw S, Isaakidis P, Khogali M, Reid A, Hoa N, Zaw KK, Aung ST.

Infect Dis Poverty. 2017 Mar 24;6(1):59. doi: 10.1186/s40249-017-0263-9.

35.

First- and second-line antituberculosis drug resistance patterns among previous treatment failure patients in Myanmar.

Nyunt WW, Aung ST, Lwin T, Cook GM, Aung HL.

J Glob Antimicrob Resist. 2017 Jun;9:34-35. doi: 10.1016/j.jgar.2017.02.007. Epub 2017 Mar 18. No abstract available.

PMID:
28323227
36.

Draft Genome Sequences of Two Drug-Resistant Mycobacterium tuberculosis Isolates from Myanmar.

Aung HL, Tun T, Permina E, Nyunt WW, Aung ST, Thinn KK, Crump JA, Cook GM.

Genome Announc. 2016 Oct 27;4(5). pii: e00850-16. doi: 10.1128/genomeA.00850-16.

37.

Community health worker in hard-to-reach rural areas of Myanmar: filling primary health care service gaps.

Sommanustweechai A, Putthasri W, Nwe ML, Aung ST, Theint MM, Tangcharoensathien V, Wynn SS.

Hum Resour Health. 2016 Oct 21;14(1):64.

38.

Whole-genome sequencing of multidrug-resistant Mycobacterium tuberculosis isolates from Myanmar.

Aung HL, Tun T, Moradigaravand D, Köser CU, Nyunt WW, Aung ST, Lwin T, Thinn KK, Crump JA, Parkhill J, Peacock SJ, Cook GM, Hill PC.

J Glob Antimicrob Resist. 2016 Sep;6:113-117. doi: 10.1016/j.jgar.2016.04.008. Epub 2016 May 30.

39.

Timing of antiretroviral therapy and TB treatment outcomes in patients with TB-HIV in Myanmar.

Thi AM, Shewade HD, Kyaw NT, Oo MM, Aung TK, Aung ST, Oo HN, Win T, Harries AD.

Public Health Action. 2016 Jun 21;6(2):111-7. doi: 10.5588/pha.16.0009.

40.

Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction.

Chan LL, Lim CP, Aung ST, Quetua P, Ho KL, Chong D, Teo WS, Sim D, Ching CK.

Singapore Med J. 2016 Apr;57(4):182-7. doi: 10.11622/smedj.2016072.

41.

Chyluria.

Aye UT, Aung ST.

Clin Radiol. 1975 Apr;26(2):237-42.

PMID:
1149383

Supplemental Content

Support Center